GM-CSF as an adjunct to autologous bone marrow transplantation.
Patients with cancer can now benefit from intensive drug dosage. Intensive drug dosage has become more effective because of the availability of better anti-emetics, hematopoietic growth factors such as granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte CSF (G-CSF), erythropoietin, etc. and improvements in hematopoietic stem cell transplantation. We have evaluated the clinical and cost effectiveness of GM-CSF in patients undergoing autologous bone marrow transplantation (AuBMT) for Hodgkin's disease. Administration of GM-CSF after AuBMT enhances myeloid and platelet recovery and is cost effective in the treatment of patients with relapsed Hodgkin's disease who received intensive chemotherapy and AuBMT. We also describe the use of various new therapeutic approaches with emphasis on clinical and cost benefit. Further work is needed to improve the route and duration of growth factor(s) infusion and the timing of the various treatments.
Gulati
S
S
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Bennett
C
C
Phillips
J
J
Van-Poznak
C
C
D000970:Antineoplastic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003365:Costs and Cost Analysis; D004311:Double-Blind Method; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000191:economics / Q000627:therapeutic use*; D006689:Hodgkin Disease / Q000188:drug therapy / Q000191:economics / Q000601:surgery; D006801:Humans; D014182:Transplantation, Autologous
D000970:Antineoplastic Agents; D016178:Granulocyte-Macrophage Colony-Stimulating Factor